HRMY
Harmony Biosciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$42.25
+0.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 959.9M | 868.5M | 714.7M | 582.0M | 437.9M |
| Cost of Revenue | 235.9M | 198.3M | 156.8M | 121.2M | 83.5M |
| Gross Profit | 724.0M | 670.1M | 557.9M | 460.8M | 354.4M |
| Operating Expenses | |||||
| R&D Expense | 220.9M | 189.6M | 145.8M | 76.1M | 70.9M |
| SG&A Expense | 272.5M | 272.0M | 221.3M | 192.7M | 163.3M |
| General & Admin Expense | 147.9M | 152.5M | 110.4M | 95.3M | 84.0M |
| Selling & Marketing Expense | 124.5M | 119.5M | 110.9M | 97.4M | 79.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 493.3M | 461.6M | 367.1M | 268.8M | 234.2M |
| Cost and Expenses | 729.2M | 660.0M | 523.9M | 390.0M | 317.7M |
| Operating Income (EBIT) | 230.7M | 208.5M | 190.8M | 192.0M | 120.2M |
| Non-Operating | |||||
| Interest Income | 24.4M | 21.9M | 18.5M | 14.7M | 3.1M |
| Interest Expense | 13.5M | 14.6M | 17.5M | 23.8M | 18.8M |
| Net Interest Income | 10.9M | 7.3M | 1.0M | (9.0M) | (15.7M) |
| Other Non-Op Income/Expense | 10.6M | 6.6M | 978.0K | (18.6M) | (15.5M) |
| Non-Operating Income (excl Interest) | (20.4M) | (21.2M) | (18.5M) | (5.1M) | (3.3M) |
| EBT (Pre-Tax Income) | 241.2M | 215.1M | 191.8M | 173.4M | 104.7M |
| Income Tax Expense | 59.9M | 56.4M | 46.3M | 44.5M | (76.8M) |
| Bottom Line | |||||
| Net Income | 181.3M | 158.7M | 145.5M | 128.9M | 181.5M |
| Earnings from Cont. Ops | 181.3M | 158.7M | 145.5M | 128.9M | 181.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 181.3M | 158.7M | 145.5M | 128.9M | 181.5M |
| Per Share | |||||
| Basic EPS | $3.13 | $2.76 | $2.56 | $2.17 | $3.07 |
| Diluted EPS | $3.08 | $2.71 | $2.51 | $2.13 | $2.97 |
| Revenue Per Share | $16.59 | $15.11 | $12.56 | $9.79 | $7.40 |
| Shares | |||||
| Basic Shares Outstanding | 57.9M | 57.5M | 56.9M | 59.5M | 59.2M |
| Diluted Shares Outstanding | 58.8M | 58.5M | 57.9M | 60.4M | 61.1M |
| Profitability Metrics | |||||
| EBITDA | 276.4M | 255.0M | 233.4M | 221.5M | 146.9M |
| D&A | 25.3M | 25.3M | 24.1M | 24.4M | 23.4M |
| EBIT | 251.1M | 229.7M | 209.3M | 197.2M | 123.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026